Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes

By Motif June 6, 2019 No Comments

Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes

https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-FDA-meeting-minutes-06.06.19.pdf

Get MotifBio Email Alerts Subscribe

About Us

Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA.

Navigation

About Motif
Iclaprim
Investors
News Releases
Contact Us

Contact Us

Motif Bio plc
201 Temple Chambers
3-7 Temple Avenue
London EC4Y 0DT
United Kingdom

Motif BioSciences Inc.
125 Park Avenue, 25th Floor
New York, NY 10017
United States
General: info@motifbio.com
Investors: ir@motifbio.com

Home
About
Development Programs
Partnering
Investors
Contact

Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes